ABVX
Abivax (NASDAQ: ABVX) plunged 32% after its experimental ulcerative colitis pill obefazimod posted...
Article Summary
HOLD- Abivax (NASDAQ: ABVX) plunged 32% after its experimental ulcerative colitis pill obefazimod posted stronger-than-expected late-stage trial results, but headline numbers were overshadowed by rare rare malignancy events.
- Abivax ADR's Paris-listed shares sank more than 32% in early European trading after roughly half of patients on both doses of the oral drug achieved clinical remission, with roughly half achieving clinical remission on the 25-milligram dose and 51.3% on the 50-mg dose compared with 10.4% on placebo.
- The results came in well above expectations and appeared to outperform existing therapies, though the report was clouded by rare, scattered cases deemed unrelated to the treatment that nonetheless rattled investors and weighed heavily on the stock.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 0.0% | 25% | 20.0 ptsMinimal (0.0%) - Very weak |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 64.2% | 20% | 100.0 ptsMassive Upside (64.2%) - Target: $147.13 vs Current: $89.59 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | -39.8% | 15% | 80.0 ptsSolid Dip (-39.8%) - Good entry zone |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About ABVX
- ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
- Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
- The company was incorporated in 2013 and is headquartered in Paris, France.